Alcon AG vs ProShares Ultra QQQ ETF — how do they compare? Alcon AG trades at $72.42 (market cap $36.44B), while ProShares Ultra QQQ ETF trades at $92.72. The key difference: Alcon AG pays a 0.48% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | QLD | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.12 | $100.53 |
52-Week Low | $62.02 | $57.16 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
QLD, the ProShares Ultra QQQ ETF, trades at $92.56, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF, offering 2x daily leverage on the Nasdaq-100, has delivered over 10,000% total return since inception, though it carries amplified risk. Recent institutional buying includes 180 Wealth Advisors increasing its position by 29.4% in Q2 2026, signaling confidence in tech exposure.
The outlook for QLD hinges on tech sector performance, with AI optimism and easing geopolitical tensions as tailwinds. However, leveraged ETF structure risks decay in volatile markets, and a 63.80% historical drawdown underscores volatility. Investors seeking aggressive tech growth may find opportunity, but must tolerate significant swings; diversification and risk management are critical.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →